欧洲缺铁性贫血治疗市场 – 行业趋势和 2030 年预测

欧洲缺铁性贫血治疗市场分析及规模

贫血是当今最常见的血液疾病之一。静脉注射铁剂因其透析外治疗质量的提高、透析患者数量的增加、全球糖尿病患者数量的增加以及老龄化人口的增加而受到广泛使用。缺铁性贫血治疗的研发将为多家制造商创造竞争优势，这些制造商拥有新的创新疗法，能够以有效方式开发和评估缺铁性贫血疗法。

Data Bridge Market Research 分析了 2023-2030 年预测期内欧洲缺铁性贫血治疗市场的增长率。在上述预测期内，欧洲缺铁性贫血治疗市场的预期复合年增长率约为 16.5%。2022 年市场价值为 10.856 亿美元，到 2030 年将增长至 36.836 亿美元。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、渠道分析、定价分析和监管框架。

欧洲缺铁性贫血治疗市场范围和细分

Market Definition

Iron deficiency anemia is a type of anemia that occurs when the body's iron stores are reduced. Anemia is specified by an inadequacy of healthy red blood cells. RBCs supply oxygen to human tissues. Iron is important in the production of haemoglobin. Haemoglobin deficiency shows lack of oxygen in the body. It's essential to keep your iron levels in check. Consumption of iron-rich foods such as meat, vegetables, fruits, and cereals can help to treat or prevent iron deficiency. Vitamin C can help to prevent iron deficiency.  

Europe Iron-Deficiency Anemia Therapy Market Dynamics

Drivers

• Rising Incidences of Chronic Kidney Disease

According to the records of National Kidney Foundation, Inc., the two primary causes of chronic kidney disease are diabetes and hypertension. Data shows that about 10% of the European population is affected by chronic kidney disease, with more than 2 million individuals getting dialysis on a regular basis.  Large number of individuals who are suffering from this disease are not aware until serious symptoms appear. It is anticipated that chronic kidney cases will rise across highly economic countries, such as India and China that infers an increase in the aged population over the upcoming years. 

• Growing Adoption of Oral Iron Therapy

The oral iron therapy is anticipated to witness huge growth during the forecast period due to the factors such as rise in the patient population suffering from anemia and anemia-causing diseases. In addition to this, increasing number of research that supports the use of oral iron therapy as a substitute to intravenous treatments in hospital settings is also anticipated to increase the adoption of oral iron therapy among people, thus boosting the segment growth

Opportunities

• Increase in Anaemia

 According to the records of the National Heart, Lung, and Blood Institute, an expected 3 million individuals suffer from anaemia in Europe. Rising incidence of target diseases, such as rheumatoid arthritis, autoimmune diseases, kidney conditions, liver disorders, thyroid diseases, cancer, and inflammatory bowel diseases, is a primary factor helping in the growth of the market for intravenous iron. According to the records of WHO, about 42% of children below the age of 5 years and 40% of pregnant women suffer from some form of anaemia. Therefore, it creates opportunity for the market growth.

• Increasing Incidence of Cancer

A rising number of cancer patients tend to develop iron deficiency anemia. Common types of cancer that are widely associated with anemia includes bone cancer, cervical cancer, blood cancer, colon cancer, and prostate cancer. Lung and breast tumors have been specified with the highest prevalence of anemia among solid tumors. Hematologic malignancies such as lymphoma, leukemia, and multiple myeloma produce abnormal blood cells that as a result harm the immune system and cause anemia. Cancer treatments such as chemotherapy and radiation therapy also increase anemia in cancer patients. This creates more opportunities in the market.

Restraints/Challenges

• Stringent Regulations by Different Associations

Numerous strict regulations are related with the intravenous iron drugs. Various government associations, such as FDA and European Medicines Agency have imposed stringent regulations for intravenous iron drugs approval and usage which takes longer to get approved and launched. Therefore, it hampers the market growth.

• Serious Effects of Iron Supplements

There are few adverse effects that are related with the intake of iron drugs. Common effects of include digestive problems such as loss of appetite, constipation, nausea, stomach aches, and vomiting. The overdose of these drugs may also lead to tiredness or weakness, shallow or rapid breathing, convulsions, fatigue, bluish skin, pale skin or fingernails. Thus, this hampers the market growth.

This Europe iron-deficiency anemia therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe iron-deficiency anemia therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19  Impact on Europe Iron-Deficiency Anemia Therapy Market

The COVID-19 outbreak has disturbed the manufacturing and supply of intravenous iron drugs, however, increased initiatives by manufacturers and government to meet the demand has aided the growth of the market for intravenous iron drugs. In addition to this, numerous studies have recommended that Covid-19 infection has a huge risk of Acute Kidney Injury (AKI) and CKD, which, in turn, has fuelled the demand for intravenous iron drugs to treat CKD-related anemia. Health authorities advised that COVID-19 patients with an acute kidney injury should be tested often as their risk of developing CKD is higher than others. Thus, COVID-19 had a major impact on the market growth.

Europe Iron-Deficiency Anemia Therapy Market Scope

The Europe iron-deficiency anemia therapy market is segmented on the basis of therapy, therapy areas, population, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy

• Parenteral Iron Therapy
• Oral Iron Therapy

Therapy Areas

• Inflammatory Bowel Disease
• Renal
• Obstetrics and Gynecology
• Congestive Heart Failure (CHF)
• Oncology
• Others

Population

• Adults
• Pediatric
• Geriatric

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Iron-Deficiency Anemia Therapy Market Regional Analysis/Insights

The Europe iron-deficiency anemia therapy market is analyzed and market size insights and trends are provided by therapy, therapy areas, population, distribution channel and end-user as referenced above.

The major countries covered in the europe iron-deficiency anemia therapy market report are the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

Germany is leading the market because of the quality and management of health care system, growing research and development activities of anemia drugs among scientists. Also, increased awareness, growing investment by government firm and presence of generic players is leading the market growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Europe Iron-Deficiency Anemia Therapy Market Share Analysis

欧洲缺铁性贫血治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对欧洲缺铁性贫血治疗市场的关注有关。

欧洲缺铁性贫血治疗市场的主要参与者包括：

• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 拜耳公司（德国）
• Cipla Inc.（美国）
• 雅培（美国）
• AbbVie Inc.（美国）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• Hikma Pharmaceuticals PLC（英国）
• Covis Pharma GmbH（美国）
• PHARMACOSMOS A/S（丹麦）
• Vifor Pharma Management Ltd.（瑞士）
• Orion 公司 (芬兰)
• Shield Therapeutics（英国）
• Advanz 制药 (英国)
• Alkem Labs（印度）

SKU-52742